CANbridge Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CANbridge Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 42.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%
Nov 14CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
Sep 27Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop
Aug 07CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too
Apr 23CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings
May 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CANbridge Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2024 | 105 | -408 | -254 | -217 | N/A |
3/31/2024 | 104 | -393 | -286 | -247 | N/A |
12/31/2023 | 103 | -379 | -319 | -278 | N/A |
9/30/2023 | 95 | -416 | -316 | -291 | N/A |
6/30/2023 | 87 | -453 | -314 | -304 | N/A |
3/31/2023 | 83 | -468 | -305 | -292 | N/A |
12/31/2022 | 79 | -483 | -296 | -281 | N/A |
9/30/2022 | 66 | -733 | -340 | -327 | N/A |
6/30/2022 | 54 | -982 | -384 | -373 | N/A |
3/31/2022 | 42 | -1,089 | -599 | -591 | N/A |
12/31/2021 | 31 | -1,077 | -461 | -587 | N/A |
9/30/2021 | 27 | -1,055 | -391 | -515 | N/A |
6/30/2021 | 22 | -1,034 | -321 | -443 | N/A |
3/31/2021 | 18 | -828 | -218 | -196 | N/A |
12/31/2020 | 12 | -846 | -305 | -152 | N/A |
12/31/2019 | 1 | -218 | -169 | -126 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1228's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1228's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1228's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1228's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1228's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1228's Return on Equity is forecast to be high in 3 years time